Page 113 - Athletic Health Handbook
P. 113
References

1. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl.
1999;56:18-24.

2. Kujubu D, Fletcher B, Varnum B, et al. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells,
encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem. 1991;266:12866-72.

3. O’Banion M, Winn V, Young D. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory
cyclooxygenase. Proc Natl Acad Sci USA. 1992;89:4888-92.

4. Xie W, Chipman J, Robertson D, et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated
by MRNA splicing. Proc Natl Acad Sci. USA 1991;88:2692-96.

5. Kargman S, Charleson S, Cartwright M, et al. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey
and human gastrointestinal tracts. Gastroenterology. 1996;111:445-54.

6. Ofman J, MacLean C, Straus W, et al. A metaanalysis of severe upper gastrointestinal complications of nonsteroidal
anti-inflammatory drugs. J Rheumatol. 2002;29:804-12.

7. Stichtenoth D, Frolich J. COX-2 and the kidneys. Curr Pharm Des. 2000;6:1737-53.
8. Mehallo C, Drezner J, Bytomski J. Practical management: Nonsteroidal anti-inflammatory drug (NSAID) use in athletic

injuries. Clin J Sport Med. 2006;16:170-74.
9. Houglum J. Pharmacologic considerations in the treatment of injured athletes with nonsteroidal anti-inflammatory drugs.

J Athl Train. 1998;33:259-63.
10. Murnaghan M, Li G, Marsh D. Nonsteroidal anti-inflammatory drug-induced fracture nonunion: An inhibition of

angiogenesis? J Bone Joint Surg Am. 2006;88-A(S3):140-7.
11. Nadarajah A, Abrahan L, Lau F, et al. Efficacy and tolerability of celecoxib compared with diclofenac slow release in the

treatment of acute ankle sprain in an Asian population. Singapore Med J. 2006;47-534-42.
12. Rahusen F, Weinhold P, Almekinders L. Nonsteroidal anti-inflammatory drugs and acetaminophen in the treatment of an

acute muscle injury. Am J Sports Med. 2004;32:1856-59.
13. Warden S. Cyclo-oxygenase-2 inhibitors: beneficial or detrimental for athletes with acute musculoskeletal injuries.

Sports Med. 2005;35:271-83.
14. Hertel J. The role of nonsteroidal anti-inflammatory drugs in the treatment of acute soft tissue injuries. J Athl Train.

1997;32:350-8.
15. Hawkey C. COX-2 inhibitors. Lancet. 1999;353:307-14.
16. McAdam B, Catella-Lawson F, Mardini I, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the

human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA. 1999;96:272-77.
17. Ahmad S, Kortepeter C, Brinker A, et al. Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf.

2002;25:537-44.
18. Sandhu G, Heyneman C. Nephrotoxic potential of selective cyclooxygenase-2 inhibitors. Ann Pharmacother. 2004;38:700-4.
19. Cryer B. A COX-2 specific inhibitor plus a proton-pump inhibitor: is this a reasonable approach to reduction in NSAID’s

GI toxicity? Amer J Gastroenterology. 2006;101:701-10.
20. Peura D, Lanza F, Gostout C, et al. The American College of Gastroenterology Bleeding Registry: preliminary findings.

Am J Gastroenterol. 1997;92:924-28.
21. US Food and Drug Administration. Alert for healthcare professionals: non-selective non-steroidal anti-inflammatory drugs

(NSAIDs). 2006. http://www.fda.gov/cder/drug/infoSheets/HCP/NSNSAIDsHCP.htm. Accessed July 12, 2006.

COX-2 INHIBITORS AND NON-SELECTIVE NSAIDS 113
   108   109   110   111   112   113   114   115   116   117   118